Certainly it is possible that monetary issues are in play, however, it is even simpler than that I think... we all have biases. As an example, if I were a urologist, or especially a urologic oncologist (if there is such a thing), then I would see all of the worst possible cases of prostate cancer and come to believe that this was a scourge that needed to be found and stopped at any cost and likely come to believe that all the biopsies and surgeries that I did to stop this scourge were justified. On the other hand, if I were a family doctor or a geriatrician and dealt with the long term side effects of the biopsies and surgeries such as incontinence or impotence and saw that the majority of prostate cancers are actually slow growing and non-metastatic then I would likely have a different view. The growing feeling is that perhaps people who have a better view of the 'big picture' related to the burden of illness, the burden of screening and treatment, and health economics are better positioned to make better recommendations. Most physicians never see rare adverse outcomes related to their interventions (or they see few enough that they can rationalize them to bad luck) but when one starts looking at populations then the view can change dramatically. A 1 in 10,000 procedure related mortality rate is very low but if you or your loved one turns out to be the death then it hits home and one would really like to be absolutely sure that the procedure was justified.
It is likely that the system in the US is more prone to being influenced by monetary issues than those of countries with more organized health care systems. Recommendations regarding routine (and even selective) PSA screening tend to be against in almost every other country that makes a recommendation. Here is a
good article looking at this from last year (Prostate screening is discussed after breast, cervical and colorectal cancer). You will note that the USPSTF recommendation changed (from against screening to selective screening in the 55 to 69 age groups) from 2012 to 2017. There was much discussion about why this happened and what the rationale was (there was a suspicion that this was related to lobbying as it was felt by many that the evidence did not justify a change). It is interesting to see that the American Cancer Society (ACS) is even more likely to recommend screening - again, there world view is different.